Ultime notizie per INmune Bio (NASDAQ:INMB) Azioni

INmune Bio

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.

INmune Bio Inc

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge. 
What Happened: On Saturday, in a post on X, Shkreli forecasted a potential 90% drop in the shares of biotech startup, Inmune Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>), a clinical-stage biotechnology company that is focused on using a patient&#8217;s immune system to fight cancers.
According to Shkreli, there&#8217;s a &#8220;very good chance $INMB will be at 0.50 on Monday,&#8221; a 90.61% drop from its closing price of $5.33 per share on Friday. 
This comes just days after the company&#8217;s shares surged 44% following a <a href="https://www.benzinga.com/news/health-care/25/06/46142036/inmune-bio-stock-soars-friday-on-alzheimers-treatment-hopes">burst of investor enthusiasm</a> surrounding its neuroinflammation candidate, XPro1595, which targets alzheimer&#8217;s disease and other central nervous system disorders. 
See Also: <a href="https://www.benzinga.com/news/health-care/25/06/46073349/why-inmeds-alzheimers-drug-candidate-is-fueling-sudden-stock-surge">Why InMed&#8217;s Alzheimer&#8217;s Drug Candidate Is Fueling Sudden Stock Surge?</a>
While the former CEO of Retrophin and Turing Pharmaceuticals, popularly referred to as &#8220;Pharma Bro,&#8221; has failed to elaborate on his predictions in the post, he did do a comprehensive video takedown of the stock nearly two weeks ago, clearly outlining his critique of the company, its science and disclosures.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Martin Shkreli Exposes The HUGE Red Flags in This Biotech Stock INMB" width="500" height="281" src="https://www.youtube.com/embed/Xu5RWAWv2Jk?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Among Shkreli's key concerns was the lack of robust Phase 1 trial data and the absence of any peer-reviewed publication supporting the candidate's efficacy. 
He also criticized the study design for not including a placebo arm, which means there was no control group to compare outcomes against, making it difficult to determine whether any observed improvements were actually due to the drug or simply a placebo effect.
Inmune Bio did not immediately respond to Benzinga&#8217;s requests for a comment on this matter. This story will be updated as soon as we hear back.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">very good chance <a href="https://twitter.com/search?q=%24INMB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$INMB</a> will be at 0.50 on Monday
&mdash; Martin Shkreli (@MartinShkreli) <a href="https://twitter.com/MartinShkreli/status/1938576339247726848?ref_src=twsrc%5Etfw">June 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Last week, Shkreli&#8217;s claims received the backing of BMF Reports, an activist short-seller, which reiterated similar concerns in <a href="https://bmfreports.com/articles/inmb">its</a> short report, such as the flawed science, dubious trial designs, and even accounting improprieties, with millions having been paid to &#8220;ghost consultants.&#8221;
While <a href="https://www.benzinga.com/general/biotech/24/01/36754161/pharma-bro-martin-shkreli-cannot-return-to-drug-industry-ever-court-upholds-lifetime-ban">banned from returning</a> to the pharmaceuticals industry ever again due to his antitrust violations, Shkreli regularly comments on stocks on his X account alongside his YouTube channel.
Over a month ago, Shkreli shared similar views on <a href="https://www.benzinga.com/markets/equities/25/05/45367829/pharma-bro-martin-shkreli-rips-into-quantum-stocks-nothing-is-happening-accuses-ionq-d-wave-quantum-and-others-of-revenue-gimmicks">quantum computing stocks</a>, forecasting 90% downsides while accusing them of inflating their financial narratives to mislead investors. He believed that a quantum computing revolution was at least 50 years away.
&#8220;[The] Global Risk Institute interviewed 24 quantum computing experts who agreed it&#8217;s 20-30 years before we see RSA2048 broken. 20-30 years before quantum works. I say 50,&#8221; he said.
Price Action: Shares of Inmune Bio were down 15.13% on Friday, closing at $5.33 per share, and are down another 16.32% after hours.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="146" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30015941/Screenshot-2025-06-30-at-11.29.21-AM-1024x146.png" alt="" class="wp-image-966267" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30015941/Screenshot-2025-06-30-at-11.29.21-AM-1024x146.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30015941/Screenshot-2025-06-30-at-11.29.21-AM-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30015941/Screenshot-2025-06-30-at-11.29.21-AM-768x110.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30015941/Screenshot-2025-06-30-at-11.29.21-AM.png 1526w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The stock scores low on Benzinga&#8217;s Edge Stock Rankings, but has a favorable price trend in the short, medium and long terms. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> for more insights on the stock. 
Photo Courtesy: Martin Gregor on Shutterstock.com
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46067629/hims-ceo-slams-novo-nordisk-for-anticompetitive-demands-after-ozempic-maker-abruptly-ends-partnership-we-refuse-to-be-strong-armed">Hims CEO Slams Novo Nordisk For &#8216;Anticompetitive Demands&#8217; After Ozempic Maker Abruptly Ends Partnership: &#8216;We Refuse To Be Strong-Armed&#8217;</a></li>
</ul>

News

Short Sellers

Short Ideas

Small Cap

Trading Ideas

INMB

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

WIIM

INmune Bio shares are trading higher. Maxim Gorup maintained a Buy rating on the stock.

Maxim Group analyst Jason McCarthy maintains INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) with a Buy and lowers the price target from $30 to $8.

Price Target

Analyst Ratings

Maxim Group Maintains Buy on INmune Bio, Lowers Price Target to $8

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>TD Securities analyst Andrew Charles downgraded the rating for Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) from Buy to Hold and lowered the price target from $25 to $15. Sweetgreen shares closed at $14.88 on Monday. <a href="https://www.benzinga.com/quote/sg/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Todd Thomas downgraded the rating for Lineage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) from Overweight to Sector Weight. Lineage shares closed at $43.52 on Monday. <a href="https://www.benzinga.com/quote/line/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst George Farmer downgraded INmune Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) from Sector Outperform to Sector Underperform and lowered the price target from $23 to $0.6. INmune Bio shares closed at $2.31 on Monday. <a href="https://www.benzinga.com/quote/inmb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Myles Allsop downgraded Southern Copper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) from Buy to Neutral and announced a $105 price target. Southern Copper shares closed at $101.17 on Monday. <a href="https://www.benzinga.com/quote/scco/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Noah Poponak downgraded the rating for Textron Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) from Buy to Neutral and slashed the price target from $95 to $85. Textron shares closed at $80.29 on Monday. <a href="https://www.benzinga.com/quote/txt/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TXT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/TXT/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="570" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01125819/image-1-4-1024x570.png" alt="" class="wp-image-969032" style="width:586px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01125819/image-1-4-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01125819/image-1-4-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01125819/image-1-4-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01125819/image-1-4.png 1127w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46192054/cramer-backs-this-mining-giant-after-1-6b-bet">Cramer Backs This Mining Giant After $1.6B Bet</a> </li>
</ul>
Photo via Shutterstock

Markets

LINE

SCCO

This Textron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

INmune Bio shares are trading lower after Scotiabank downgraded the stock from Sector Outperform to Sector Underperform and lowered its price target from $23 to $0.6. BTIG downgraded the stock from Buy to Neutral.

BTIG analyst Thomas Shrader downgrades INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) from Buy to Neutral.

Downgrades

BTIG Downgrades INmune Bio to Neutral

Scotiabank analyst George Farmer downgrades INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) from Sector Outperform to Sector Underperform and lowers the price target from $23 to $0.6.

Scotiabank Downgrades INmune Bio to Sector Underperform, Lowers Price Target to $0.6

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 0.3% on Monday.
The Dow traded up 0.45% to 44,014.63 while the NASDAQ gained 0.32% to 20,338.93. The S&amp;P 500 also rose, gaining, 0.33% to 6,193.57.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46168293/top-2-consumer-stocks-that-are-ticking-portfolio-bombs">Top 2 Consumer Stocks That Are Ticking Portfolio Bombs</a>
Leading and Lagging Sectors Financials shares jumped by 0.8% on Monday.
In trading on Monday, consumer discretionary stocks fell by 0.8%.
Top Headline
Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) and Juniper Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) reached an agreement with the U.S. Department of Justice (DOJ) on Saturday.
This settlement, subject to court approval, resolves the DOJ's lawsuit that challenged HPE's acquisition of Juniper and paves the way for the transaction to close.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Bitmine Immersion Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NASDAQ">BMNR</a>) shares shot up 442% to $23.10 after the company announced a $250 million private placement to launch an Ethereum treasury strategy.</li>
<li>Shares of Artelo Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) got a boost, surging 102% to $13.70 after the company announced data from its first-in-human study for ART26.12.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares were also up, gaining 15% to $10.81 after the company announced it completed a series of test flights in Dubai.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Fortive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) shares dropped 5% to $51.03 as the company announced the completion of the Ralliant separation and appointment of Olumide Soroye as President, CEO and Director of Fortive.</li>
<li>Shares of INmune Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) were down 59% to $2.1680 after the company announced its Phase 2 MINDFuL trial did not meet its primary cognitive endpoint.</li>
<li>Chemed Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) was down, falling 15% to $475.29 after B of A Securities cut its price target on the stock from $708 to $650.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $65.03 while gold traded up 0.5% at $3,304.40.
Silver traded down 0.5% to $36.20 on Monday, while copper fell 0.8% to $5.0820.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.42%, while Spain's IBEX 35 Index gained 0.16%. London's FTSE 100 fell 0.43%, Germany's DAX 40 declined 0.51% and France's CAC 40 slipped 0.33% during the session.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei gaining 0.84%, Hong Kong's Hang Seng Index falling 0.87%, China's Shanghai Composite gaining 0.59% and India's BSE Sensex falling 0.54%.
Economics
<ul class="wp-block-list">
<li>The Chicago PMI fell to 40.4 for June from 40.5 in May, and compared to market estimates of 42.7.</li>
<li>The Dallas Fed's general business activity index for Texas manufacturing climbed to a reading of -12.7 in June compared to -15.3 in the previous month.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46168575/wall-streets-most-accurate-analysts-spotlight-on-3-defensive-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

ARTL

BMNR

JNPR

JOBY

Crude Oil Moves Lower; Joby Aviation Shares Surge

<h3>Gainers</h3>
<ul>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) shares moved upwards by 113.0% to $14.46 during Monday's regular session. The market value of their outstanding shares is at $3.7 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock increased by 61.1% to $1.16. The market value of their outstanding shares is at $26.2 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares rose 54.24% to $1.64. The market value of their outstanding shares is at $132.4 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) stock rose 33.94% to $2.13. The company's market cap stands at $11.8 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock moved upwards by 24.27% to $0.64. The company's market cap stands at $15.7 million. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) stock moved upwards by 22.97% to $0.53. The market value of their outstanding shares is at $10.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) shares decreased by 59.9% to $2.14 during Monday's regular session. The company's market cap stands at $124.6 million. </li>
<li>Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) shares decreased by 31.55% to $0.53. The market value of their outstanding shares is at $13.2 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock declined by 30.27% to $0.06. The company's market cap stands at $32.7 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock decreased by 29.96% to $2.87. The company's market cap stands at $154.0 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock declined by 27.8% to $4.91. The market value of their outstanding shares is at $82.0 million. </li>
<li>Odysight ai (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODYS#NASDAQ">ODYS</a>) shares decreased by 27.44% to $5.09. The company's market cap stands at $114.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACXP

KLTO

NCNA

ODYS

ONMD

SERA

UNCY

12 Health Care Stocks Moving In Monday's Intraday Session

INmune Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) stock is trading lower on Monday, with a session volume of 23.2 million, compared to the average volume of 1.45 million, <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">as per data from Benzinga Pro</a>.
The company announced results from its Phase 2 MINDFuL trial evaluating XPro, a selective soluble TNF inhibitor, in early Alzheimer&#8217;s Disease with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">biomarkers of inflammation</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44846884/europe-approves-eisai-biogens-alzheimers-drug-under-strict-conditions-after-initial-negative-opinion" rel="noreferrer noopener">Europe Approves Eisai-Biogen&#8217;s Alzheimer&#8217;s Drug &#8216;Under Strict Conditions&#8217; After Initial Negative Opinion</a>
Despite showing no effects in the modified intent-to-treat population (mITT, n=200), predefined analyses demonstrated a cognitive benefit for XPro&nbsp;over placebo on the primary endpoint EMACC, a behavioral benefit on the Neuropsychiatric Inventory, and a biological benefit on pTau217 in early Alzheimer&#8217;s patients with two or more biomarkers of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46165425/inmune-bio-reports-key-findings-from-phase-2-mindful-trial-of-xpro-in-early-alzheimers-disease" rel="noreferrer noopener">inflammation at baseline (n=100)</a>.
The MINDFuL trial enrolled 208 participants.
The primary endpoint was the change in cognition over 6 months as measured by the Early Mild Alzheimer&#8217;s Cognitive Composite (EMACC), a cognitive assessment specifically designed to measure change in early AD patients.
While the primary endpoint was not met in the mITT group, key changes in clinical measures of cognition, behavior, and an AD-related biomarker demonstrated a benefit in a subpopulation of patients treated with XPro over patients treated with placebo.
Key Findings in the Amyloid positive Early AD participants with two or more biomarkers of inflammation (N=100):
<ul class="wp-block-list">
<li>A clinical benefit of XPro over placebo was observed on the primary endpoint EMACC (effect size: 0.27) and the secondary endpoint Neuropsychiatric Inventory (effect size: -0.24).</li>
<li>A biological benefit of XPro over placebo was observed in blood levels of pTau217 (effect size: -0.20), the gold standard measure of AD pathology in the blood.&nbsp;</li>
<li>XPro treatment was safe and well tolerated, without any occurrences of ARIA-E or ARIA-H.</li>
<li>The study demonstrates that it is possible to safely target neuroinflammation in patients where neuroinflammation is a driver of AD pathology.</li>
</ul>
Additional analyses are underway and will be presented at AAIC in July.
Based on the totality of the data, the company intends to:
<ul class="wp-block-list">
<li>File for Breakthrough Therapy Designation with the FDA.</li>
<li>Schedule an End-of-Phase 2 meeting with the FDA in Q4 2025 to define the path for a pivotal trial to support XPro approval in early AD.</li>
</ul>
On Friday, INmune Bio announced a registered direct offering of 3 million shares at $6.30 per share, with approximately <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46145913/inmune-bio-inc-announces-approximately-19-million-registered-direct-offering-priced-at-the-market-" rel="noreferrer noopener">$19 million in gross proceeds</a>.
The company intends to use the net proceeds for working capital and general corporate purposes.
Price Action: INMB stock is down 59% at $2.14 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46169804/gorilla-technology-grrr-stock-falls-after-105m-offering" target="_blank" rel="noreferrer noopener">Gorilla Technology (GRRR) Stock Falls After $105M Offering</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Biotech

Health Care

General

Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Monday.
Following the market opening Monday, the Dow traded up 0.32% to 43,958.43 while the NASDAQ gained 0.23% to 20,319.78. The S&amp;P 500 also rose, gaining, 0.20% to 6,185.68.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46168293/top-2-consumer-stocks-that-are-ticking-portfolio-bombs">Top 2 Consumer Stocks That Are Ticking Portfolio Bombs</a>
Leading and Lagging Sectors Financials shares jumped by 0.6% on Monday.
In trading on Monday, utilities stocks fell by 0.5%.
Top Headline
The Chicago PMI fell to 40.4 for June from 40.5 in May, and compared to market estimates of 42.7.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Bitmine Immersion Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NASDAQ">BMNR</a>) shares shot up 315% to $17.22 after the company announced a $250 million private placement to launch an Ethereum treasury strategy.</li>
<li>Shares of Artelo Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) got a boost, surging 183% to $19.21 after the company announced data from its first-in-human study for ART26.12.</li>
<li>Professional Diversity Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares were also up, gaining 139% to $4.18 after gaining 12% on Friday.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>JVSPAC Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JVSA#NASDAQ">JVSA</a>) shares dropped 65% to $3.75. Hotel101 Global received an approval to list on NASDAQ under "HBNB".</li>
<li>Shares of INmune Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) were down 61% to $2.08 &nbsp;after the company announced its Phase 2 MINDFuL trial did not meet its primary cognitive endpoint.</li>
<li>Dogness (International) Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) was down, falling 56% to $12.68.</li>
</ul>
Commodities In commodity news, oil traded down 0.6% to $65.15 while gold traded up 0.2% at $3,295.40.
Silver traded down 0.5% to $36.195 on Monday, while copper fell 1.1% to $5.0685.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.4%, while Spain's IBEX 35 Index slipped 0.1%. London's FTSE 100 fell 0.3%, Germany's DAX 40 declined 0.6% and France's CAC 40 slipped 0.3% during the session.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei gaining 0.84%, Hong Kong's Hang Seng Index falling 0.87%, China's Shanghai Composite gaining 0.59% and India's BSE Sensex falling 0.54%.
Economics
The Chicago PMI fell to 40.4 for June from 40.5 in May, and compared to market estimates of 42.7.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46168575/wall-streets-most-accurate-analysts-spotlight-on-3-defensive-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Defensive Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

DOGZ

IPDN

JVSA

Dow Gains Over 100 Points; Chicago PMI Weakens In June

INmune Bio shares are trading lower after the company announced its Phase 2 MINDFuL trial did not meet its primary cognitive endpoint.

<h3>Gainers</h3>
<ul>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) stock moved upwards by 165.2% to $18.01 during Monday's pre-market session. The company's market cap stands at $3.7 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares rose 41.64% to $1.02. The company's market cap stands at $26.2 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock rose 25.68% to $2.74. The market value of their outstanding shares is at $4.0 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) shares increased by 22.68% to $1.99. The market value of their outstanding shares is at $120.4 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock moved upwards by 22.04% to $11.57. The market value of their outstanding shares is at $246.6 million. </li>
<li>Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) shares rose 14.48% to $1.66. The market value of their outstanding shares is at $17.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) shares fell 57.4% to $2.27 during Monday's pre-market session. The market value of their outstanding shares is at $124.6 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) shares fell 31.06% to $2.82. The market value of their outstanding shares is at $154.0 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock declined by 20.4% to $1.6. The market value of their outstanding shares is at $5.5 million. </li>
<li>Odysight ai (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODYS#NASDAQ">ODYS</a>) shares decreased by 20.12% to $5.6. The market value of their outstanding shares is at $114.3 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock declined by 16.92% to $5.65. The company's market cap stands at $82.0 million. </li>
<li>MEI Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) shares decreased by 16.08% to $2.35. The market value of their outstanding shares is at $18.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

LIMN

MEIP

QTTB

VERO

12 Health Care Stocks Moving In Monday's Pre-Market Session

<ul>
<li>In the Phase 2 MINDFuL trial of XPro in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined population of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100), a benefit of XPro&#x2122; treatment over placebo was observed in cognitive, behavioral and biological endpoints.</li>
<li>Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients. The most common adverse events (AE) were injection site reactions.</li>
<li>Additional analyses will be presented at Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-31, 2025) and the Company will submit for Breakthrough Therapy designation with the FDA.</li>
</ul>

INmune Bio Says Phase 2 MINDFuL Trial Evaluating XPro In Early Alzheimer's With Biomarkers Of Inflammation Did Not Meet The Primary Cognitive Endpoint

Shares of Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) rose sharply in today's pre-market trading after Madryn Asset Management increased its <a href="https://www.benzinga.com/quote/VERO">stake in the company to 85.5%</a>.
Venus Concept shares jumped 32.5% to $2.91 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Professional Diversity Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) surged 233.7% to $5.84 in pre-market trading after gaining 12% on Friday.</li>
<li>Klotho Neurosciences, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) gained 37.8% to $0.9926 in pre-market trading. Klotho Neurosciences advanced KLTO-202 gene therapy manufacturing to treat ALS with Neuroprotective s-KL RNA splice variant.</li>
<li>Bitmine Immersion Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NASDAQ">BMNR</a>) climbed 20.3% to $5.13 in pre-market trading. BitMine recently completed a $16.35 million bitcoin purchase for its treasury.</li>
<li>FGI Industries Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) rose 16.5% to $0.6635 in pre-market trading after falling around 9% on Friday.</li>
<li>MingZhu Logistics Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) gained 13.6% to $1.17 in pre-market trading after dipping 7% on Friday.</li>
<li>Perfect Moment Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#NASDAQ">PMNT</a>) rose 12.1% to $0.2735 in pre-market trading after dipping 42% on Friday.</li>
<li>Eupraxia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPRX#NASDAQ">EPRX</a>) gained 12.1% to $5.94 in pre-market trading after jumping 15% on Friday.</li>
<li>Juniper Networks, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) surged 8.5% to $39.93 in pre-market trading. HPE and Juniper Networks reached a settlement with the U.S. Department of Justice.</li>
<li>Wearable Devices Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>) jumped 6.4% to $1.51 in pre-market trading after falling 7% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>INmune Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) shares tumbled 46.7% to $2.84 in pre-market trading after falling 15% on Friday. INmune Bio revealed top-line results from its MINDFuL Phase 2 trial.</li>
<li>Argo Blockchain plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) dipped 34% to $0.24 in pre-market trading.</li>
<li>JVSPAC Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JVSA#NASDAQ">JVSA</a>) dipped 33.7% to $7.09 in pre-market trading. Hotel101 Global received an approval to list on NASDAQ under &#8220;HBNB&#8221;.</li>
<li>Sera Prognostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) fell 32.7% to $2.75 in pre-market trading after jumping 107% on Friday.</li>
<li>Blue Gold Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGL#NASDAQ">BGL</a>) declined 27.5% to $45.31 in pre-market trading after gaining over 210% on Friday.</li>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) fell 21.8% to $1.57 in pre-market trading. Autonomix Medical shares jumped over 60% on Friday after the company announced it was granted a US Patent for its catheter-based platform technology.</li>
<li>Bone Biologics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) declined 19.4% to $3.69 in pre-market trading. Bone Biologics shares gained 10% on Friday after the company announced it filed a USPTO patent for rhNELL-1..</li>
<li>RedCloud Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCT#NASDAQ">RCT</a>) fell 18.5% to $2.64 in pre-market trading after gaining 126% on Friday.</li>
<li>Iron Horse Acquisitions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IROH#NASDAQ">IROH</a>) shares fell 15.9% to $9.25 in pre-market trading after gaining 11% on Friday.</li>
<li>Tronox Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) fell 10.6% to $5.05 in pre-market trading.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46136470/jim-cramer-just-revealed-1-oil-stock-he-actually-wants-to-own">Jim Cramer Just Revealed 1 Oil Stock He Actually Wants To Own</a></li>
</ul>

Pre-Market Outlook

ARBK

BBLG

EPRX

IROH

PMNT

TROX

WLDS

YGMZ

Why Venus Concept Shares Are Trading Higher By Over 32%; Here Are 20 Stocks Moving Premarket

INMB stock has given up its prior gain. INmune Bio shares were trading higher after the company revealed top-line results from its MINDFuL Phase 2 trial.

<a href="https://x.com/adamfeuerstein/status/1938636778950602947">https://x.com/adamfeuerstein/status/1938636778950602947</a>

STAT News Biotech Reporter Adam Feuerstein Posts On X "$INMB raised money today with full knowledge of the Alzheimer's study data, per a source familiar with the transaction."

INmune Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering (the "Offering") at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules.
The closing of the Offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $19 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the Offering for working capital purposes and general corporate procedures.

Offerings

INmune Bio Prices 3M Share Registered Direct Offering At $6.30/Shr

INmune Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) stock is trading higher on Friday, with a session volume of 10.26 million compared to the average volume of 519.5K, <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">per data from Benzinga Pro</a>.
On Thursday,  INmune Bio said it will host a conference call on Monday, June 30, to present topline data from the Phase 2 MINDFuL trial in early <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Alzheimer&#8217;s disease</a>.
The MINDFuL study investigates XPro in patients with mild cognitive impairment or Alzheimer's disease with brain inflammation.
The MINDFuL study <a href="https://inmunebio.com/index.php/clinical-trials/mindful-section" target="_blank" rel="noreferrer noopener">will</a> compare XPro to placebo (an injection that looks like the investigational drug but does not contain active medicine) to determine whether XPro affects memory, functioning and behavior, and whether it is safe and tolerable.
In November 2024, INmune Bio completed randomization of patients for <a href="https://www.benzinga.com/pressreleases/24/11/g41939489/inmune-bio-inc-announces-final-enrollment-of-208-patients-in-phase-2-trial-in-early-alzheimers-dis" target="_blank" rel="noreferrer noopener">its Phase 2 trial</a>. &#8220;The trial ended up overenrolled with a total of 208 patients, 56% of whom were categorized as mild AD and 44% as MCI,&#8221; said RJ Tesi, CEO of INmune Bio
In September 2024, the company announced that the results of an additional analysis of blinded data from its AD02 Phase II Alzheimer&#8217;s Disease trial demonstrated&nbsp;exceptional performance of the novel cognitive measure EMACC and a highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40897550/inmune-bio-announces-results-of-additional-blinded-interim-analysis-of-phase-2-alzheimers-disease-" rel="noreferrer noopener">accepted endpoint for AD trials.</a>
Key Findings: An independent review confirmed a highly significant correlation (p&lt;0.001) between baseline scores on EMACC and CDR-SB, the secondary endpoint in the AD02 trial.
The correlation of EMACC, when measured during the screening process and again at the first study visit before treatment, was found to be 0.93.
The difference in EMACC performance between patients with CDR global ratings of 0.5 (prodromal AD) and those rated 1.0 (mild dementia) was very large, with an effect size (Cohen&#8217;s d) of 0.87 (p&lt;.0001)
XPro is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors.
XPro could have potential substantial beneficial effects in patients with neurologic disease by <a href="https://www.benzinga.com/pressreleases/25/06/g46127038/inmune-bio-inc-to-announce-top-line-results-from-mindful-phase-2-trial-in-early-alzheimers-on-mond" target="_blank" rel="noreferrer noopener">decreasing neuroinflammation</a>.
INMB Price Action: INMB stock is up 74.68% at $10.97 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/46138385/deal-dispatch-darden-bahama-breeze-nba-ma-heats-up" target="_blank" rel="noreferrer noopener">Deal Dispatch: Darden Cools On Bahama Breeze, NBA M&amp;A Heats Up</a></li>
</ul>
Photo: khunkornStudio via Shutterstock

INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes

Press Releases

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference

XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer's Disease: Supported by Department of Defense

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Comments

INmune Bio

Notizie

Ultime notizie per INmune Bio (NASDAQ:INMB) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO